Copyright © Inderes 2011 - present. All rights reserved.
Log ind for at modtage meddelelser.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Scandidos

1,28

 

SEK

 

+1,99 %

Mindre end 1K følgere

SDOS

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Ownership
Investor consensus
Sammenligne
+1,99%
-1,16%
-11,72%
-28,89%
-22,89%
-25,58%
-41,55%
-44,1%
-90,74%

Scandidos are active in medical technology. The company provides products and systems for quality assurance of advanced radiation therapy against cancer. The systems analyze the radiation dose before and during ongoing radiation treatment. The company was founded in 2002 and the first product was launched in 2006. Since its inception, Scandidos has delivered products to radiation therapy clinics on a global level. The head office is located in Uppsala.

Læs mere
Markedsværdi
72,97 mio. SEK
Aktieomsætning
46,16 t SEK
Omsætning
60,43 mio.
EBIT %
-22,31 %
P/E
-
Udbytteafkast, %
-
Finanskalender
18.6
2025

Årsrapport '25

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse21.11.2024, 09.20

ScandiDos Expands with New Reference Center in Madrid, Spain

Scandidos
Pressemeddelelse18.4.2024, 11.00

Successful user meeting in Madrid highlights ScandiDos' innovative solutions

Scandidos
Selskabsmeddelelse20.12.2023, 08.03

ScandiDos receives orders worth €478 000 from China

Scandidos

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Selskabsmeddelelse30.11.2023, 07.15

ScandiDos AB changes Certified Adviser and liquidity provider to Carnegie Investment Bank AB (publ)

Scandidos
Selskabsmeddelelse29.11.2023, 15.34

ScandiDos achieves EU Medical Device Regulation certification for the Delta4 Phantom+ product line

Scandidos
Selskabsmeddelelse28.6.2023, 08.55

ScandiDos receives orders worth €290 000 from China

Scandidos
Pressemeddelelse13.5.2023, 08.00

ScandiDos and IBA Dosimetry deepen strategic alliance!

Scandidos
Selskabsmeddelelse14.3.2023, 12.00

ScandiDos receives an order worth €263 000 from China

Scandidos
Pressemeddelelse23.2.2023, 07.30

ScandiDos sees growing demand for patient-specific QA in Chinese market

Scandidos
Selskabsmeddelelse1.11.2022, 12.50

ScandiDos receives an order of € 377 500 from Japan

Scandidos
Pressemeddelelse2.9.2022, 12.30

ScandiDos’ directed share issue completed

Scandidos
Selskabsmeddelelse30.8.2022, 16.00

ScandiDos has completed a directed share issue of 4,150,000 shares at a subscription price of SEK 3 per share

Scandidos
Selskabsmeddelelse25.2.2022, 07.50

ScandiDos launches Delta4 Insight which is immediately available to sell to customers in Europe and parts of Asia.

Scandidos
Selskabsmeddelelse16.2.2022, 07.00

ScandiDos Celebrates 20th Anniversary

Scandidos
Selskabsmeddelelse4.3.2021, 15.36

ScandiDos: Leading centers all over the world select Scandidos' Delta4 Phantom+ MR for their MR-linac programs

Scandidos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.